目的 本研究探讨了肝内胆管癌(ICC)患者多梳蛋白SUZ12的表达及其在预测ICC患者的生存和对治疗反应的作用.方法 用免疫组织化学方法检测207个肝组织样本(包括ICC患者,胆道上皮内瘤样病变患者BilIN-1,-2,-3,和非瘤样病变的胆管样本)SUZ12和p16INK4a蛋白的表达.评估这些蛋白的表达是否和接受化疗的ICC患者的病理学特征和生存结果相关,以及是否和随后的化疗反应相关.结果 从非肿瘤性胆管组织依次到BilIN-1,-2,-3,ICC,SUZ12表达水平渐进增加.而p16INK4a蛋白在非瘤样病变性胆管组织中大量表达,但在BilIN-1,-2,-3,ICC组织中依次逐渐降低.SUZ12表达与未分化的ICC、淋巴结转移和晚期癌症相关.Kaplan-Meier曲线分析显示,高表达SUZ12的ICC患者与低表达SUZ12的ICC患者相比,总生存期和无瘤生存期显著降低.SUZ12表达与接受吉西他滨为基础的辅助化疗(Adjuvant gemcitabine-based chemotherapy,AGC)的患者的总体存活显著相关.结论 SUZ12表达能够预测用吉西他滨为基础的化疗的ICC患者的总生存期和无病生存期.%Objective This study explored the expression of polyclonal protein SUZ12 in patients with intrahepatic cholangiocarcinoma(ICC),and its role in predicting the survival and treatment of ICC patients.Methods The expression of SUZ12 and p16INK4a was detected by immunohistochemical assay in 207 liver tissue samples including ICC patients,BilIN-1,-2,-3 and non-tumor-like cholangiocarcinoma.The expression of these proteins was assessed to be related to the pathological characteristics of the ICC patients receiving chemotherapy and the outcome of survival as well as the subsequent chemotherapy response.Results The expression level of SUZ12 was gradually increased from non-neoplastic bile duct tissue to BilIN-1,-2,-3 and ICC.The expression of p16INK4a protein was expressed in non-neoplastic-like cholangiocarcinoma,but it decreased gradually in BilIN-1,-2,-3 and ICC tissues.SUZ12 expression was associated with undifferentiated ICC,lymph node metastasis and advanced cancer.Kaplan-Meier curve analysis showed that ICC patients with high expression of SUZ12 had a significant reduction in overall survival and disease-free survival in comparison with ICC patients with the low expression of SUZ12.SUZ12 expression was significantly associated with overall survival of patients receiving adjuvant gemcitabine-based chemotherapy(AGC).Conclusion SUZ12 expression is able to predict the overall survival and disease-free survival of ICC patients with adjuvant gemcitabine-based chemotherapy.
展开▼
